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ABSTRACT  
A reusable low cost microfluidic cell culture array device (MCCAD) integrated with a six 
output concentration gradient generator (cGG) and 4 × 6 arrays of microchamber elements, 
addressed by a series of row and columnar pneumatically actuated normally closed (NC) 
microvalves was fabricated for cell-based screening of chemotherapeutic compounds. The poly 
(dimethylsiloxane) (PDMS) device consists of three layers: fluidic, control and membrane which 
2are held by surface contact and made leak-proof by clamping pressure. The NC valves are 
actuated by a thick PDMS membrane that was created by a novel method based on the self-
assembly of PDMS pre-polymer molecules over a denser calcium chloride solution. The 
membrane actuated the valves reliably and particulates such as alumina particles (3 μm) and 
MCF-7 cells (20-24 μm) (2 × 105 cells/mL) were flowed through the valves without causing 
blockage or leakage and consequently avoiding contamination of the different cell culture 
elements. 
The MCCAD was cast and assembled in a standard laboratory without specialist equipment 
and demonstrated for performing quantitative cell-based cytotoxicity assays of pyocyanine on 
human breast cancer (MCF-7) cells and assessed for toxic effect on human hepatocyte carcinoma 
(HepG2) cells as an indicator for liver injury. Then, the MCCAD was demonstrated for 
sequential drug combinatorial screening involving gradient generation of paclitaxel doses
followed by treatment with aspirin doses on the viability of MCF-7 cells. The interaction 
between paclitaxel and aspirin was evaluated by using the Bliss independence predictive model 
and results showed reasonable agreement with the model. A robust, portable, easily fabricated 
and low cost device is therefore shown to conveniently carry out culturing of multiple cell lines 
for high throughput screening of anti-cancer compounds using minimal reagents. 
Keywords: Microfluidic, Normally closed valve, Cell culture array, Combinatorial screening, 
Cytotoxicity assay. 
31. Introduction 
Drug discovery and development is a complex, lengthy and costly process which requires 
drugs to be tested for efficacy and toxicity in humans [1]. There is a high level of attrition of 
drug candidates, with only one in ten of those entering clinical trials becoming finally approved. 
Currently, drug development processes are mainly conducted using standardised macroscopic 
systems which incorporate automated analysis and robotics in a high-throughput manner, but 
these have drawbacks including high cost. Cell culture models are increasingly used to predict 
clinical response to drugs, this approach has the advantage of providing a more representative 
response to drugs than simple biochemical assays as well as obviating the need for whole animal 
testing which is lengthy, expensive and raises ethical issues. Cellular assays are often conducted 
in multi-well plates but suffer from a number of drawbacks including uncontrolled evaporation 
and inability to model multi-organ interactions.  
The potential importance of microfluidic platforms in drug development has been widely 
recognised [2]. Microfluidic cell culture platforms integrated with key functional elements such 
as microvalves, mixers, gradient generators, detectors and heating elements are applicable for a 
variety of applications including a microchemostat [3]. They offer advantages in high-throughput 
screening owing to their ability to reduce amount of sample and reagent consumptions, precise 
control of fluids, automation, reduction of time and cost of conducting cell culture experiments 
and the potential to more accurately mimic the in vivo cellular microenvironment. Microfluidic 
systems have generally made use of large scale integration of pneumatically controlled 
microvalves pioneered by Quake and co-workers [4], these are broadly categorised as either the 
normally Open (NO) or normally Closed (NC). 
Many of the previously reported cell culture array devices [5, 6] use pneumatically controlled 
valves that are of the NO type [4]. These valves are costly to fabricate and require special flow 
4channels with rounded cross sectional geometry. The lithographic mould manufacture for the NO 
valves requires a two stage process. In the first stage, SU-8 is exposed under a negative mask, the 
second stage uses a standard positive photoresist that requires accurate alignment under a 
positive mask and then a post-processing reflow process to achieve the rounded shape [4]. In the 
case of the NC valves there is only requirement for a single stage lithographic process using SU-
8. For cell culturing, the flow requirements include loading of cells into the cell culture elements 
and periodic perfusion to feed the cells. In the case of multiple cell types, there is also a 
requirement for isolation of individual cell culture elements to prevent contamination. A NO 
valve type requires constant actuation to hold the valves shut and has limited fluidic channel 
aspect ratios since the membrane is required to stretch into the channel for sealing. The NC is fail 
safe and may be disconnected from the pneumatic system without leakage and contamination 
between the different cell culture elements. In the NC valves the thickness of the PDMS 
membrane has been shown to have little effect on the actuation pressure of the valve [7]. Thicker 
membranes are preferable since they are easier to handle, actuate reliably and easy to fabricate.  
Here we report on the development of a PDMS MCCAD platform which integrates a two 
input cGG with six outlets that delivers into an array of 4 × 6 culture chamber elements 
addressed by row and columnar NC valves to direct and control fluid flow on the device. A novel 
low cost technique for producing membranes without the need for cleanroom facilities, for 
actuating the valves is described. In general, PDMS membranes are prepared by spin coating to a 
thickness down to 10 m. The proposed method is based on the self-assembly of prepolymer 
molecules controlled by the surface tension difference between a salt solution and the PDMS 
prepolymer. We found this to be a simple and low cost method for the preparation of membranes 
5down to 20 µm. The utility of the MCCAD was demonstrated for cell-based cytotoxicity and 
toxicity assays on MCF-7 cells and HepG2 cells. 
2. Materials and methods
2.1. Design and fabrication of MCCA Chip  
The fluidic pathways of the MCCAD were designed in AutoCAD 2007 (Autodesk, USA), as 
shown in Fig. 1A. A 100μm thick membrane was sandwiched between the two PDMS layers and 
separates the fluidic and control layers. There are interruption gaps of 100 µm on the floor of the 
fluidic microchannels (300 µm width, 200 µm depth) to define the valve seat. The control layer 
microchannels (200 µm wide, 200 µm depth) have an expanded terminal end to define the valve 
displacement chamber. The valve arrays (columnar and row) are controlled by two independent 
vacuum lines referred to as Group 1 and Group 2 (Fig. 1B) which are automated via LabVIEW 
8.6 (National Instruments). Every microchamber is controlled by two pairs of microvalves to 
prevent cross contamination across the chambers and to allow loading of different cells on the 
cell culture chip (Fig. 1C). The fluidic and control layers were cast in PDMS (Dow Corning 
Sylgard 184) from an SU-8 master mould that had been made using standard lithographic 
procedures [8]. 
2.2. Preparation of PDMS membrane 
The PDMS membrane was prepared using a simpler and cheaper novel method than the 
conventional way of spin coating, where a 10:1 (wt/wt) of the base and the curing agent were 
thoroughly mixed and degassed (30 min). The PDMS prepolymer was poured over a denser 
CaCl2 solution contained in a Petri dish. The CaCl2 solution (~15 mL, 400 g/L), filtered at room 
temperature, was transferred to a Petri dish (90 mm diameter) on a flat level surface. The less 
6dense PDMS spreads evenly by natural reflow on the surface of the CaCl2 solution creating a 
thin film. The volume of PDMS defines the thickness (tm) of the film according to equation (1). 
Equation 1 
Where V is the volume of PDMS, d is the diameter of the petri-dish.  
The developed PDMS membrane was cured at 60 ºC for 2 h and removed gently from the salt 
solution followed by cleaning with 70% ethanol to remove any salts from the surface of the 
membrane. 
2.3. Assembling of MCCAD 
The MCCAD was packaged and assembled as shown in Fig.1A using standard techniques [4]. 
The PDMS membrane (thickness 100 µm) was sealed to the control layer by a small clamping 
pressure. Small fluidic vias (1 mm diameter) were punctured on the PDMS membrane for the 
inlet and outlet ports. The non-structured side of the fluidic layer was sealed on a glass slide to 
provide support and the control layer pressure sealed to the PDMS membrane. The two 
composite layers were then aligned and pressure sealed under a magnifying glass. The structure 
was then clamped between PMMA sheets (thickness 3 mm) to seal it and support. Food colour 
dyes (red and green) were introduced in the assembled device to test the seal integrity of the 
valves and assess the performance of the gradient generator as described by Jeon et al.[9]. The
presence of the air bubbles was avoided by ensuring that all the chip layers and potential 
openings were properly sealed to avoid leakage. The device was sealed by clamping the chip 
between two PMMA sheets and also the culture media was degassed using an ultrasonic bath.
2.4 Cell culture and cell seeding
MCF-7 and HepG2 cells were a donation from the Northern Institute for Cancer Research-
Newcastle University. MCF-7 and HepG2 cells were separately cultured in Eagle's minimal 
7essential medium (EMEM) supplemented with 2 mM L-glutamine, 1% non-essential amino 
acids, 10% FBS and 1% penicillin/ streptomycin/amphotericin in 75 mm2 flasks at 37 °C, 5% 
CO2 humidified incubator until they reached 90% confluency. All cell culture media were 
purchased from Sigma Aldrich (UK). Cells were passaged a maximum of 4 times before being 
cultured on the cell culture array. Prior to loading cells, the MCCAD was sterilized by UV-
radiation (30 mins) followed by flushing the fluidic connections with 70% ethanol and rinsed 
with sterile phosphate buffer solution (PBS). Sterile fibronectin solution (100 µg/mL in PBS) 
was then used to coat the microchambers for 12 h at 4 ºC. Cells were trypsinised, centrifuged, 
and the desired number of cells from each suspension were counted and used for seeding the 
MCCAD. MCF-7 and HepG2 cell suspensions (2 × 105 cells/mL respectively) were seeded into 
the cell culture chambers when valves under Group 1 control line are open. After cell seeding, 
the Group 1 valve array was switched off, PTFE tubes removed and the inlet and outlet ports 
were sealed with silicone tape. The MCCAD was placed in an incubator and maintained at 37 ºC 
and 5% CO2 for 4-6 h for cell attachment. The attached cells were allowed to proliferate and 
maintained for 24 h by flowing sterile degassed EMEM medium (3.5-5 µL/min) over a 2 min 
period through the cell culture device at 4 h intervals over a period of 24 h to feed the cells. This 
approach allowed metabolised media to be replenished periodically without exerting significant 
hydrodynamic shear stress on the cells. 
82.5 Cytotoxicity and toxicity assays 
After 24 h, MCF-7 and HepG2 cells were simultaneously exposed for 6h to different 
concentrations of pyocyanine (Sigma Aldrich-UK) from the cGG. A stock solution of 
pyocyanine (100 µM) and EMEM were introduced into the inlets C and D of the cGG (Fig.1B) 
and downstream culture chambers achieved pyocyanine concentration of (0, 20, 40, 60, 80 and 
100 µM) respectively. The MCF-7 and HepG2 cells exposed to pyocyanine were treated with 2 
μM calcien AM diluted in non-phenol red Dulbecco's Modified Eagle's Medium (DMEM) media 
for 30 min to assess cell viability. Calcien AM (Sigma Aldrich-UK) is a non-fluorescent dye that 
permeates easily in live cells and is hydrolysed intracellularly by esterases enzymes in the 
cytoplasm to calcien which produces green fluorescence. Cell imaging was carried out with a 
TE-2000 Nikon fluorescence microscope equipped with a low light intensity monochromatic 
CCD camera using the 4X and 10X objectives. Viable cells were enumerated by counting the 
green fluorescent cells. Cell viability after pyocyanine treatment was expressed as percentage of 
live cells, in each chamber treated with the chemical relative to the number of live cells in a 
control.
Drug combination assays were conducted by exposing MCF-7 cells seeded in the 
microchamber elements of the MCCAD to a sequential combination of paclitaxel and aspirin 
(Sigma Aldrich-UK) doses. Aspirin and paclitaxel were dissolved in dimethyl sulfoxide (DMSO) 
and further diluted with Eagle's minimal essential medium (EMEM) to final concentrations of 10 
mM and 1.2 µM respectively. Initially MCF-7 cells were exposed to concentrations of paclitaxel 
(0, 0.2, 0.5, 0.7, 0.9 and 1.2 µM) from the cGG for 6 h followed by sterile phosphate buffer rinse 
The MCF-7 cells were then exposed for 6 h to concentrations of the second drug aspirin (0, 2, 4, 
96, 8 and 10 mM) respectively, followed by assessing cell viability with calcien AM as described 
for the pyocyanine assays.
Conventional 96 culture well plates were seeded with the same cell density for MCF-7 and 
HepG2 cells as for the MCCAD and incubated at 37 °C and 5% CO2 for 24 h followed by 
challenging cells with the respective drug doses. Cell viability was assessed as previously 
described for the MCCAD. 
Fig. 1.
3 Results and discussion  
3.1. Design of the MCCAD
The integration of various commonly used fluidic components (gradient generator, and 
microvalves) as part of the MCCAD offers several advantages including reducing the number of 
mixing and pipetting steps and consequently experimental error. Normally PDMS devices are 
permanently bonded using either oxygen plasma or curing, the MCCAD platform uses surface 
contact and a clamping force to provide a seal for leak-proof operation. The reversible sealing 
between the layers allows the device to be reused and with the different parts being able to be 
cleaned or replaced. A further advantage is that the alignments of the three layers is not time 
constrained and so are less susceptible to damage, unlike when oxygen plasma bonding is used. 
A drawback of PDMS based devices is that they cannot be manufactured at high volume so the 
approach described here reduces the number of devices that need to be fabricated reducing effort 
and cost of device fabrication. In large scale integrated microfluidic systems, microvalves are 
required to be leak-proof (tight seal integrity), scalable and carry out multiplexing for 
individually addressing each element of cell culture array [11, 12]. The NC valve design is fail 
safe in that when no vacuum is applied they are closed which prevents contamination between 
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the adjacent culture chambers. Moreover, the NC valve design is easy to integrate with complex 
microfluidic platforms and does not require pressure to close them, thus making it highly 
portable without leaking or mixing of cell culture chamber contents. The opening pressure of the 
NC valve depends on the thickness of the membrane, the mechanical and bulk properties of the 
membrane material, adhesion forces between the membrane and the valve stop and dimensions 
of the vacuum well. 
The cells used in this study were between 20-24 m and to avoid clogging within the device 
we choose the fluidic architecture to have larger channel dimensions of 300 m × 200 m. As a 
consequence a larger displacement chamber of 600 m × 600 m was used which allows a 
thicker PDMS membrane. Different membrane thicknesses (50-125 µm) were investigated for 
their effect on the opening of the valve and a linear relationship was observed between the 
membrane thickness and the opening pressure. A membrane thickness of 100m was chosen for 
ease of handling and a vacuum of 80 kPa was required to fully open the valve. The NC type 
valves have been less well studied within the literature for tolerance to particulate flow. The 
valves were first tested for robustness to particulates using different sizes and concentrations of 
particles. A suspension of 0.01 g/mL alumina particles with particle diameter of 3 µm were 
found to flow through the valves. Subsequently, testing of clogging arising from human cells was 
tested using trypsinised suspensions of MCF-7 cells (20-24 m) (2 × 105cells/mL) and these 
were also found to flow through the valves and not clog the microfluidic channels or disrupt the 
valve operation. 
A standard gradient generator was designed to output 0-100% concentration solutions in 20% 
steps [9]. The performance of the cGG was tested using a standard stock solution of pyocyanine 
(100 µM) and EMEM with the final concentrations of pyocyanine being determined by 
11
absorbance using linear interpolation with a standard calibration curve and results compare well 
with literature reports [13]. 
3.2. Cell culture in the MCCAD
We demonstrated the ability of the MCCAD to sustain cell proliferation by culturing, MCF-7 
and HepG2 within the different culture chamber elements without compromising the integrity of 
each cell type through contamination. Fig. 2 shows representative microscopic images of seeded 
MCF-7 and HepG2 cells in the respective culture chamber elements. The results showed that 
both the MCF-7 and HepG2 cells proliferated well in the cell culture environment with good 
morphology. These findings demonstrated the suitability of the substrate material, method of 
periodic perfusion of culture media and that the general experimental approach was appropriate 
for cell growth. A fed-batch method was used to periodically replenish culture media and 
removal of cellular waste products every 4 h. This approach has the advantage of shielding cells 
from being exposed to the effects of high hydrodynamic shear stress gradients which may be 
produced during continuous perfusion of media and adversely affect cellular behaviour rendering 
them unsuitable for experimental work. In contrast to bacterial cells, mammalian cells do not 
have a cell wall and are therefore susceptible to the effects of hydrodynamic shear stress. The use 
of PDMS as a material substrate for the MCCAD was found to be suitable for performing long 
term cell culturing experiments. PDMS has a number of desirable properties including non-
toxicity, optical transparency and permeability to O2 and CO2. The relatively high permeability 
allows exchange of gases between the external atmosphere of the chip and medium in the culture 
chambers and consequently supports proliferation of the cells. PDMS is, however, susceptible to 
non-specific protein adsorption which can result in depletion of protein levels within the medium 
and affect the consistency of culture conditions and cellular behaviour [14]. A variety of 
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pharmaceutical compounds can be adsorbed on the PDMS material and this can vary depending 
on factors such as pH and the ions in solution [15]. Sorption of the cytotoxic agent by PDMS 
will result in lowering of the cytotoxicity concentration which further complicates the analysis. 
Interference from sorption effects are reduced by coating the cell culture wells with fibronectin 
molecules to render them hydrophilic and biocompatible for cell adhesion.
Fig. 2.
3.3.Cytotoxicity and toxicity assays 
MCF-7 and HepG2 cells were used as simple models for breast cancer tissue and the liver 
organ respectively to mimic the physiological in vivo conditions of the human body on 
cytotoxicity tests and chemical toxicity. Previous studies have shown that pyocyanine induces 
toxicity in both prokaryotes and eukaryotes cells by engaging in non-enzymatic redox reactions 
which generates reactive oxygen species (ROS) such as O2- and H2O2 [16, 17]. These ROS 
species deplete cells of NADH, glutathione and other oxidants causing oxidative stress leading to 
cell death due to DNA damage [18]. 
The efficacy of pyocyanine against MCF-7 cells was estimated from the LC50, concentration 
of the cytotoxic agent at 50% cell viability. The LC50 for pyocyanine on MCF-7 cells was 60 ± 3 
µM for the MCCAD and 51 ± 3 µM for 96 culture well plates. Some difference of this value in 
comparison with the microfluidic cell culture array can be expected since the microfluidic cell 
culture device has periodic perfusion of nutrients and the constant removal of waste. 
Conventional culture well plates operate under static conditions with uncontrolled liquid 
evaporation due to relatively high surface area to volume ratio which can result in poorly defined 
culture conditions.
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Toxicity screening assays for drugs provide crucial information on preclinical studies in 
assessing the safety aspects of the potential drug candidates [19]. The MCCAD was used to 
model the response of HepG2 liver cells to the toxic effect of pyocyanine. HepG2 cells were 
used as the model cell line because they are highly differentiated and display similar genotypic 
features typical of primary hepatocytes [20]. Experimental results showed that approximately 
70% of HepG2 cells exposed to pyocyanine concentration of 100 µM, in both the microfluidic 
device and the culture well plates, were still adherent and viable. The resistance of HepG2 cells 
to pyocyanine could be due to the higher levels of peroxidase and catalase enzymes found in 
liver hepatocytes [21]. The actual causes of resistance to pyocyanine and its mode of action is an 
area that requires further investigation. 
3.4. Drug combination treatment
    The microfluidic cell culture array platform was used to investigate the effect of exposure of 
chemotherapeutic drugs paclitaxel and aspirin, individually and as a sequential combination, on 
the viability of MCF-7 cells. MCF-7 cells were cultured in the MCCAD and exposed to the 
treatment with doses of paclitaxel and aspirin as single drugs acting alone and sequential 
combination. Cell numbers were manually counted and viability was expressed as percentage of 
live cells, in each chamber treated with the drug combinations relative to the number of live cells 
in the control. The mean values for cell responses to the combination of paclitaxel and aspirin 
doses and control conditions were fitted on linear regression curves. The fitted concentration–
response curves were used to determine the concentrations of the drug combinations. Statistical 
significance was evaluated by one way analysis of variance (ANOVA) using student’s t test. P < 
0.05 was considered as statistically significant. 
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Fig. 3 shows the fluorescent images of MCF-7 cells after exposure to either paclitaxel or aspirin 
alone and their sequential combination activity. 
Fig. 3. 
The results in Figs. 3B-C and Fig. 4A showed that the exposure of MCF-7 cells to 
concentrations of paclitaxel alone was dose dependant. The LC50 value for paclitaxel alone on 
MCF-7 cells was 0.63 ± 0.04 µM and 0.55 ± 0.05 µM for 96 culture well microplates. Paclitaxel 
inhibits and disrupts the microtubule network organisation in neoplastic tissues resulting in the 
arrest of the G2/M cell cycle and the inability of cells to properly complete mitosis [22]. 
The exposure of MCF-7 cells to concentrations of aspirin alone induced loss of viability in a 
dose dependent manner (Figs. 3D, G and 4A). MCF-7 cells exposed to 2 mM of aspirin alone 
gave a modest 5% reduction in the cell viability (Figs. 3D and 4A). At higher doses (8-10 mM) 
of aspirin, above the therapeutic plasma concentration, there was significant reduction of around 
40% on the cell viability (Fig. 4A). The LC50 for aspirin alone on MCF-7 cells in the MCCAD 
was found to be 9.8 ± 1.0 mM (Fig. 4A) and 6.9 ± 0.3 mM for 96 culture well microplates. A 
LC50 value of 6.6 mM has been previously reported for aspirin on human MCF-7 cells when 
exposed to the drug for 24 h in 96 culture well microplates [23]. The action of aspirin against 
adenocarcinomas is attributed to its ability to inhibit cyclooxygenase enzymes COX-1 and COX-
2 mostly expressed in tumor cells [24]. Aspirin facilitates the reduction in angiogenic factor 
secretion and production of prostaglandins in tumor cell activity, thus restricting tumor growth 
[25].
The use of combination of drugs, for treatment of cancer and infections, offers the potential to 
identify a lower dose for maximising cancer cell death and eradication of infections with less 
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side-effect. Combination therapy reduces the risk of drug resistance and discovery of synergies 
in a variety of diseases including tuberculosis, malaria, HIV AIDS and metastatic breast cancers 
[26]. Ovarian and breast cancer cells show some resistance to paclitaxel treatment alone and so 
combination therapy is attractive [27]. The experimental effect of paclitaxel and aspirin 
combination on the viability of MCF-7 cells is seen qualitatively from the fluorescent images in 
Fig. 3 and quantified in Fig. 4A. In Fig. 3A, MCF-7 cells exposed to the control/no drug 
treatment conditions (0 µM paclitaxel and 0 mM Aspirin), proliferated well and had higher 
viability. The exposure of MCF-7 cells to 0.2 μM of paclitaxel followed by 2 mM of aspirin 
showed 21% loss of cell viability than 17% and 6% when each drug was administered alone 
respectively (Fig. 3E).
Interestingly, it can be seen that one combination of 0.46 ± 0.07 µM of paclitaxel with 4 mM 
of aspirin gives an LC50 which is at lower drug concentrations than is the case for the use of 
individual drugs (Fig. 4A). The drawback of high drug concentrations of the individual drug 
compounds is that they may cause damage to secondary organs such as the liver or kidneys. The 
interaction between paclitaxel and aspirin was evaluated by using the Bliss Independence model 
[28, 29]. Within the experimental space of this study, the data showed reasonable agreement with 
the model and the effect of paclitaxel and aspirin on cell viability appears to be cumulative. The 
predicted cumulative effect of paclitaxel and aspirin are shown in Fig. 4B and obtained from the 
experimental individual effects of each drug given in Fig. 4A. As an example, a paclitaxel 
concentration of 0.2 µM alone reduces cell viability to 83% whilst aspirin at 4 mM concentration 
alone reduces cell viability to 84% (Fig. 4B). The predicted cumulative effect of the paclitaxel 
and aspirin, at these concentrations, will be 0.83 × 0.84 = 0.697 or 70% (Fig. 4B). It can be seen 
that the experimental observations in Fig. 4A compare well with those predicted in Fig. 4B.
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The performance of the microbioreactor array platform was compared with the conventional 
96 culture well plate at selected concentrations. Figure 5A shows the comparison of MCF-7 cells 
exposed to paclitaxel concentrations (0, 0.2, 0.5, 0.7, 0.9 and 1.2 µM) followed by exposure to 4 
mM or 10 mM of aspirin in the MCCAD and the 96 culture well plate (96 wp). MCF-7 cells 
exposed to the drug combinations treatment in the MCCAD consistently showed more growth 
than in the 96 culture well plates and so provided a better platform for detailed cell-based assay 
investigation. The LC50 values for the combination of paclitaxel doses followed by exposure to 
4mM aspirin for the MCCAD and the 96 culture well plates were 0.46 ± 0.02 µM and 0.26 ± 
0.01 µM respectively. In general, a similar trend was also obtained with other combinations 
(results not shown). It can be seen that the experimental observations in Fig. 5A for the MCCAD 
and the 96 culture well plate compare well with those predicted in Fig. 5B. The different 
response of MCF-7 cells in the MCCAD and 96 culture well plates to the combined drug 
treatment could be due to the absorption or adsorption of the drug molecules by the substrate 
material (PDMS) in the MCCAD, which could lower the concentration of the drugs giving rise to 
a reduced cytotoxicity response. 
Fig. 4. and Fig. 5. 
4. CONCLUSION 
An integrated microfluidic 24 element cell culture array using NC valves was successfully 
demonstrated for low cost cell-based screening of chemotherapeutic compounds including 
screening of drug combinations. The device was cast on an SU-8 mould in a standard laboratory 
without specialist equipment. A simple NC valve design with a thick membrane and reversible 
sealing which allowed the device to be disassembled and either cleaned for re-use or the parts 
replaced. The NC valves were shown to be robust and reliable in operation and allowed the 
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device to be disconnected and moved between for different stations for different operations. The 
system has been shown to be viable as a tool for in vitro clinical drug development. Further work 
will involve more detailed investigation of the effective dosage range as well as validating 
further possible combinations of chemotherapeutic compounds and their interaction with cell 
culture models that better recreate the complex in vivo cellular microenvironment, such as 3D 
cell culture or spheroid formats.  
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List of figures
Figure 1: Schematic of device assembling and system set up. A. Exploded 3D representation of 
MCCAD. B. Experimental set up. C. Single cell culture chamber controlled by a set of four 
microvalves to prevent cell to cell communication and contamination. D. Mechanism of opening 
and closing of a valve [10]. 
Figure 2: Seeded cells attached and localised inside the MCCAD microchambers. A. AA´ MCF-
7 and BB´ HepG2. 
Figure 3: Selected fluorescent images of MCF-7 cells taken at (4X) after sequential treatment 
with paclitaxel and aspirin. MCF-7 cells were first exposed to six concentrations (0, 0.2, 0.5, 0.7, 
0.9 and 1.2 µM of paclitaxel for 6h followed by exposure to six concentrations (0, 2, 4, 6, 8 and 
10 mM) of aspirin for further 6 h and assessed for viability with calcien AM fluorescent dye. 
Figure 4: Response of MCF-7 cells after sequential treatment with paclitaxel and aspirin in 
the MCCAD. A. The regressed data plot showing the experimental sequential combination effect 
of paclitaxel and aspirin at varying concentrations on cell viability. B. Bliss Independent 
Predicted model showing the effect of paclitaxel and aspirin at varying concentrations on MCF-7 
cell viability. The legends on A and B represent the concentration of aspirin (0, 2, 4, 6, 8, 10 
mM) in combination with the concentrations of paclitaxel respectively. Data shown represents 
the mean of three independent experiments. Error bars are plus or minus standard deviation. 
Figure 5: Comparison of MCF-7 cells after sequential treatment with paclitaxel and aspirin in 
the MCCAD and 96 culture well plates (96 wp) at selected concentrations. Sequential treatment 
of MCF-7 cells with (0.0, 0.2, 0.5, 0.7, 0.9 and 1.2 µM) of paclitaxel for 6 h followed by 
exposure to 4 mM and 10mM of aspirin for 6 h respectively. B. Bliss Independent Predicted 
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model showing the effect of paclitaxel doses (0.0, 0.2, 0.5, 0.7, 0.9 and 1.2 µM) followed by 
exposure to 4 mM and 10 mM of aspirin on MCF-7 cell viability respectively. Data shown 
represents the mean of three independent experiments. Error bars are plus or minus standard 
deviation.
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Highlights 
 Novel fabrication of PDMS membranes over calcium chloride solution  
 Integration of normally closed valves on microbioreactor array 
 Cytotoxicity and toxicity assays involving MCF7 and HepG2 cells on chip 
 Combinatorial effects of paclitaxel and aspirin on MCF-7 cells 
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